Aphios and ITC/Immune Technology to Collaborate on Natural Therapeutic for Chronic Hepatitis C
June 20, 2001
Woburn, MA — Aphios Corporation ("Aphios") and ITC/Immune Technology ("ITC") today announced a worldwide, exclusive collaboration to develop, manufacture and commercialize a natural therapeutic for Hepatitis C patients. Under the agreement, Aphios and ITC will pool their scientific resources and intellectual property, and share all costs and revenues associated with research, development and marketing of the natural Hepatitis C therapeutic. Financial terms of the agreement were not disclosed.

Chronic viral hepatitis C is a major public health concern, and a source of significant morbidity and mortality. The World Health Organization puts the global incidence of Hepatitis C at 170 million people infected. The Centers for Disease Control and Prevention (CDC) estimates that there are about three million chronically infected individuals in the United States. Without effective intervention for Hepatitis C (HCV), the CDC has predicted that the death toll will triple by the year 2010 and exceed the number of US deaths due to AIDS. Viral Hepatitis C is one of the most common causes of two fatal diseases: cirrhosis and hepatocellular carcinoma. The global HCV marketplace is estimated to be greater than $3.4 billion. At this time, there is no ideal treatment for chronic hepatitis C nor an effective immunoprophylaxis.

Dr. Trevor Castor, President and Chief Executive Officer of Aphios Corporation stated, "We are excited to be collaborating with ITC to advance our natural therapeutic research efforts in the area of Hepatitis C. ITC has extensive medical and indigenous expertise in the use of Eastern herbs for treating Hepatitis C, making them an ideal partner to expedite the development time and eventual commercial success of any product resulting from the collaboration. By pooling our collective resources, we believe this collaboration will allow us to make a truly significant discovery effort in the field."

"This collaboration with Aphios is a unique opportunity to work with a scientific team at the forefront of natural therapeutic products research and development. In addition to their broad-based capabilities in the isolation of natural medicines, Aphios has the infectious disease capabilities and facilities to conduct these types of studies," said ITC Chief Executive Officer, Marc Nehamkin. "We are very excited about the insights our researchers have gained into the natural herbal treatment for chronic Hepatitis C and look forward to contributing these insights to this collaborative endeavor."

Aphios Corporation is a biopharmaceutical company that is developing enhanced therapeutics for health maintenance and the treatment of human diseases with a focus on CNS, cancer and infectious diseases. Aphios Corporation has developed several enabling technology platforms for improving the discovery, manufacturing, delivery and safety of therapeutic drugs.

ITC/Immune Technology is an innovative research and development company focused on the discovery of promising natural treatments for HIV infection, Chronic Hepatitis, Liver Cirrhosis and COPD/asthma. Other promising research includes treatments for Crohn's disease and in microcirculation enhancement.